State Street Corp Reduces Stake in Beyond Air, Inc. (NASDAQ:XAIR)

State Street Corp lowered its position in Beyond Air, Inc. (NASDAQ:XAIR) by 34.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 100,607 shares of the company’s stock after selling 53,700 shares during the period. State Street Corp’s holdings in Beyond Air were worth $39,000 at the end of the most recent reporting period.

Separately, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Beyond Air during the 2nd quarter valued at about $47,000. 31.50% of the stock is owned by hedge funds and other institutional investors.

Beyond Air Price Performance

NASDAQ XAIR opened at $0.36 on Friday. The company has a 50-day moving average price of $0.48 and a 200-day moving average price of $0.50. Beyond Air, Inc. has a 52 week low of $0.30 and a 52 week high of $2.17. The company has a quick ratio of 5.38, a current ratio of 5.76 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $25.99 million, a P/E ratio of -0.26 and a beta of -0.23.

Beyond Air (NASDAQ:XAIR) last announced its earnings results on Monday, November 11th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. The business had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $1.19 million. Beyond Air had a negative net margin of 2,369.17% and a negative return on equity of 227.29%. During the same period in the prior year, the company earned ($0.51) earnings per share. Equities research analysts anticipate that Beyond Air, Inc. will post -0.78 earnings per share for the current year.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.